Net profit of Fredun Pharmaceuticals rose 96.62% to Rs 10.48 crore in the quarter ended December 2025 as against Rs 5.33 crore during the previous quarter ended December 2024. Sales rose 57.04% to Rs 159.93 crore in the quarter ended December 2025 as against Rs 101.84 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales159.93101.84 57 OPM %16.4612.98 - PBDT15.788.22 92 PBT14.007.13 96 NP10.485.33 97 Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live News

Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 16 February 2026.Powered by Capital Market - Live News

The board of Fredun Pharmaceuticals at its meeting held on 29 December 2025 has approved allotment of 6,44,360 equity shares at an issue price of Rs 1250 (including a premium of Rs 1240) on preferential basis for a cash consideration of Rs 80.54 crore payable in cash; The board also approved allotment of 5,51,600 convertible warrants at an exercise price of Rs 1250 per warrant aggregating to Rs 68.95 crore, upon receipt of Rs 312.50 (being 25% of the issue price of warrant) amounting to Rs 17.23 crore as subscription price. Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 127.87% to Rs 9.73 crore in the quarter ended September 2025 as against Rs 4.27 crore during the previous quarter ended September 2024. Sales rose 34.33% to Rs 143.59 crore in the quarter ended September 2025 as against Rs 106.89 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales143.59106.89 34 OPM %15.5513.04 - PBDT14.608.63 69 PBT13.007.57 72 NP9.734.27 128 Powered by Capital Market - Live News